Private Wealth Management Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Private Wealth Management Group’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.53K	Sell	121 -13	-10%	-$483	﹤0.01%	882
2026 Q1	$4.87K	Buy	+134	New	+$5.99K	﹤0.01%	782
2025 Q4	–	Sell	-68	Closed	-$2.83K	–	1486
2025 Q3	$2.83K	Buy	68 +23	+51%	+$735	﹤0.01%	998
2025 Q2	$1.29K	Sell	45 -16	-26%	-$494	﹤0.01%	1201
2025 Q1	$2.05K	Buy	+61	New	+$2.28K	﹤0.01%	1045

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Wealth Management Group's CRNX Position: Q2 2026 in Review

Private Wealth Management Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 9.7% in Q2 2026, selling an estimated $483 and leaving 121 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #882.

Private Wealth Management Group first reported a position in CRNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.87K in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Private Wealth Management Group held 121 shares of Crinetics Pharmaceuticals worth $4.53K as of Q2 2026.
Private Wealth Management Group sold 13 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $483.
Crinetics Pharmaceuticals made up ﹤0.01% of Private Wealth Management Group's portfolio in Q2 2026, its #882 holding.
Private Wealth Management Group first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
Private Wealth Management Group's Crinetics Pharmaceuticals position peaked at $4.87K in Q1 2026.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Private Wealth Management Group's 13F filing for Q2 2026, filed 27 Jul 2026.